Financial Performance - Total revenue for Q1 2024 was $510,817, a decrease of 15.6% compared to $605,844 in Q1 2023[11] - Net loss for Q1 2024 was $1,195,113, compared to a net loss of $856,554 in Q1 2023, representing an increase of 39.7%[11] - Basic and diluted loss per share for Q1 2024 was $0.78, compared to $0.56 in Q1 2023[11] - Revenue for Q1 2024 decreased by $0.1 million, or 15.7%, to $0.5 million from approximately $0.6 million in Q1 2023, primarily due to timing of rebates related to a sublicense agreement with Takeda Pharmaceuticals[65] - The net loss for Q1 2024 was approximately $1.2 million, compared to a net loss of approximately $0.9 million in Q1 2023, representing an increase in loss of $0.3 million or 39.5%[64] - Working capital decreased by $1.1 million to approximately $7.7 million at March 31, 2024, primarily due to the net loss incurred during the quarter[70] - Cash flows used in operating activities totaled approximately $1.2 million for Q1 2024, compared to approximately $1.1 million for Q1 2023, primarily due to net loss[73] Research and Development - Research and development expenses increased to $944,321 in Q1 2024, up 58.6% from $595,276 in Q1 2023[11] - Research and development expenses increased by approximately $0.3 million, or 58.6%, to approximately $0.9 million in Q1 2024 from approximately $0.6 million in Q1 2023, driven by increased spending on pre-clinical development for the DNase platform[66] - The company is focused on advancing its systemic DNase program for pancreatic carcinoma and has partnered with other companies to develop its proprietary drug delivery platform, PolyXen[21] - The company is focused on advancing its systemic DNase program as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors[61] - The Company has entered into a Research Funding and Option Agreement with Scripps Research, committing up to $0.9 million for research on the DNase oncology platform technology, with approximately $0.9 million already paid as of March 31, 2024[35] Financial Position - Cash at the end of Q1 2024 was $7,823,701, down from $11,994,827 at the end of Q1 2023, a decrease of 34.8%[17] - Total assets decreased to $9,394,096 as of March 31, 2024, down from $10,605,226 as of December 31, 2023, a decline of 11.4%[9] - Total stockholders' equity decreased to $8,677,602 as of March 31, 2024, down from $9,795,641 as of December 31, 2023, a decrease of 11.4%[9] - The accumulated deficit increased to approximately $194.4 million at March 31, 2024, compared to approximately $193.2 million at December 31, 2023[70] - The valuation allowance against deferred tax assets was approximately $40.1 million as of March 31, 2024, compared to $39.7 million as of December 31, 2023, indicating an increase of about 1.01%[50] Future Outlook - The company expects to continue incurring operating losses in the near term, raising substantial doubt about its ability to continue as a going concern[24] - The company anticipates needing additional capital in the long term to pursue its business initiatives[24] - The company anticipates needing additional capital in the long-term to pursue business initiatives, with existing resources expected to fund operations for at least twelve months[72] Legal and Compliance - The company has not received regulatory marketing authorization for any drug candidates to date, focusing on advancing the DNase technology[62] - The company has no off-balance sheet financing arrangements that could materially affect its financial condition[78] - There have been no material changes in critical accounting estimates from those disclosed in the Annual Report for the year ended December 31, 2023[80] - The management evaluated the effectiveness of disclosure controls and procedures, concluding they are effective as of the end of the reporting period[83] - There were no changes in internal control over financial reporting that would materially affect it during the reporting period[84] - The company is not currently subject to any material legal proceedings, nor are any threatened against it[86] - There have been no material changes to the risk factors previously disclosed in the Annual Report for the year ended December 31, 2023[87] - No unregistered sales of equity securities occurred during the reporting period[88] - No defaults upon senior securities were reported[89] - No director or officer adopted or terminated any trading arrangements during the quarter ended March 31, 2024[91] - The company filed various certifications in compliance with the Sarbanes-Oxley Act of 2002[93] Other Financial Activities - The Company recognized total share-based expense of approximately $0.1 million for both the three months ended March 31, 2024, and 2023[45] - No stock option awards were granted during the three months ended March 31, 2024, and 2023, with no options exercised or expired in either period[47] - The Company has approximately 462,963 Series A Warrants outstanding, exercisable at $33.00 per share, with no warrants exercised during the three months ended March 31, 2024, and 2023[42] - The Company incurred no provision for income taxes during the three months ended March 31, 2024, and 2023, due to losses in both periods[50] - The Company has paid approximately $2.5 million to Catalent for services related to the cGMP manufacturing of Human DNase I as of March 31, 2024[34] - The Company has paid approximately $0.1 million to UVA under a research agreement as of March 31, 2024, with $29,000 recognized as an advance payment[36] - For the three months ended March 31, 2024, the Company recorded royalty payments of approximately $0.5 million from Takeda, compared to $0.6 million in the same period of 2023, reflecting a decrease of about 16.67%[32]

Financial Results - Xenetic Biosciences, Inc. reported financial results for the year ended December 31, 2023, with a focus on corporate updates[6] - The press release detailing the financial results is included as Exhibit 99.1, which is referenced in the report[7] Company Classification - The company is classified as an emerging growth company under the Securities Act of 1933[5] Forward-Looking Statements - Forward-looking statements in the report are subject to risks and uncertainties, including market conditions and regulatory processes[8] - The company does not undertake any obligation to update forward-looking statements except as required by law[8] Report Signing - The report was signed by Chief Financial Officer James Parslow on March 22, 2024[13]

DNase Platform and Oncology Focus - The DNase platform targets neutrophil extracellular traps (NETs) to address inflammatory and autoimmune pathologies, as well as cancer growth and metastasis[24]. - The company is advancing its DNase platform towards a first-in-human study for IV rhDNase I in patients with locally advanced or metastatic solid tumors, focusing on high unmet needs in pancreatic cancer, colorectal carcinoma, and other gastrointestinal cancers[25]. - The DNase program is targeting multi-billion-dollar market opportunities in oncology, particularly in indications with significant unmet needs[25]. - The systemic DNase program is aimed at treating pancreatic carcinoma and other locally advanced or metastatic solid tumors, targeting multi-billion-dollar indications[48]. - The DNase platform targets NETs, which can create pro-tumorigenic niches and impede the effectiveness of existing cancer therapies[46]. - The company plans to prioritize efforts on the newly licensed DNase technology aimed at improving outcomes for solid tumors[11]. - The company is focusing on the advancement of its DNase oncology platform, targeting multi-billion-dollar indications including pancreatic carcinoma and other solid tumors[48]. - The company has exclusive license and sublicense agreements with CLS Therapeutics to develop its interventional DNase platform aimed at improving treatment outcomes, with multiple value-driving milestones expected over the next 12-24 months[48]. Pancreatic Cancer Statistics and Treatment Landscape - Approximately 185,000 individuals are diagnosed with pancreatic cancer globally each year, with an estimated 60,000 diagnoses in the U.S. in 2021[25]. - The five-year survival rate for pancreatic cancer patients is only 7-8%, with metastatic cases having a survival rate of just 3%[25]. - Current treatment options for advanced pancreatic cancer are limited, with second-line therapy yielding a median overall survival of only 4.7 months[25]. - The company emphasizes the urgent need for new therapeutic options for pancreatic cancer due to the ineffectiveness of recent developments for this patient group[25]. - The overall five-year survival rate for pancreatic cancer patients diagnosed with metastatic disease is only 3%[25]. Colorectal Cancer Statistics and Treatment Landscape - In 2023, approximately 153,000 individuals in the U.S. are estimated to be diagnosed with colon cancer, with an estimated 53,000 deaths from the disease[26]. - The 5-year survival rate for localized CRC is 91%, but drops to 72% if the cancer has spread to surrounding tissues, and to 13% if it has metastasized to distant parts of the body[26]. - The five-year relative survival rate for metastatic colorectal cancer is only 13%[26]. - Approximately 10% of all CRC cases exhibit high DNA microsatellite instability (MSI-H), with around 50% response rates to immunotherapy in this subset[28]. - For mCRC patients, chemotherapy remains the main treatment, with 95% of patients being MSS/MMRp mCRC, typically treated with fluoropyrimidine-based regimens[137]. - Immune checkpoint inhibitors are the preferred first-line therapy for the 5% of patients with MSI-H/dMMR mCRC, but 50% of these patients may fail treatment[138]. - The company is exploring novel combinations of immune checkpoint inhibitors with conventional cancer drugs to address vulnerabilities in MSS/MMRp mCRC[138]. Financial and Operational Risks - The company faces risks related to the uncertainty of financial performance and the need for substantial additional funding to achieve its goals[19]. - There is a reliance on third parties for clinical studies, which could impact the company's ability to execute its strategies effectively[19]. - The competitive environment poses challenges, as there are no assurances that competing technologies will not adversely affect the company's business development[19]. - The company has never been profitable and may require substantial additional funding to achieve its goals, which could affect its financial condition[19]. - The success of the company's business is substantially dependent on the DNase oncology platform[19]. - The company may face challenges in enrolling patients for clinical studies, which could delay or prevent the development of its pharmaceutical products[19]. Collaborations and Agreements - A collaboration with Volition aims to develop NETs-targeted adoptive cell therapies for multiple solid cancers, with shared proceeds from commercialization[31]. - The company has committed up to $938,000 to Scripps Research for advancing the pre-clinical development of its DNase oncology platform technology[42]. - The company has entered into a Research Funding and Option Agreement with Scripps Research, committing up to $938,000 for advancing the pre-clinical development of its DNase oncology platform technology, with initial and monthly payments of approximately $78,000 over 12 months[42]. - A Research Funding and Material Transfer Agreement with the University of Virginia was established to advance the systemic DNase program, with an option to acquire exclusive rights to new intellectual property arising from the research[44]. - The company has collaboration agreements with Pharmsynthez and Serum Institute for the development and potential commercialization of ErepoXen, with no revenue recognized from these agreements in 2023[67]. Regulatory Environment and Compliance - The company is subject to extensive government regulations in the U.S. and other countries regarding the research, development, testing, and marketing of its products[84]. - The FDA requires a lengthy approval process for new drugs, including preclinical testing, submission of an IND, and successful completion of clinical trials[86]. - The company must comply with Good Laboratory Practices (GLP) and Good Clinical Practice (GCP) regulations during the drug development process[86]. - The FDA may impose additional requirements, such as Phase IV trials, after initial marketing approval to monitor the safety and effectiveness of approved products[96]. - The company is required to submit annual progress reports and safety reports to the FDA during the IND phase of drug development[91]. - The approval process for an NDA or BLA can be lengthy and may result in a Complete Response Letter if deficiencies are identified, requiring resubmission[95]. - The FDA's Fast Track program allows for expedited review of new drugs intended for serious conditions, enabling rolling review of marketing application sections[100]. - Breakthrough Therapy Designation can expedite development for drugs showing substantial improvement over existing therapies, with a review of requests within 60 days[102]. - The 21st Century Cures Act established the RMAT program for regenerative medicine, facilitating development for serious conditions[103]. - The FDA may withdraw approval if regulatory compliance is not maintained post-approval, which can lead to market withdrawal[104]. Intellectual Property and Patent Strategy - The company has over 170 U.S. and international patents and pending patent applications covering various aspects of its technologies as of February 15, 2024[72]. - The patent strategy includes filing applications in major pharmaceutical markets, with existing patents for PolyXen technology expiring between 2025 and 2030[69]. - The company relies on trade secrets and know-how to maintain its proprietary position in oncology[72]. - The company plans to utilize data exclusivity and market exclusivity to strengthen its proprietary position[72]. - The first issued patents for the company's PolyXen technology began to expire in 2021, with the majority expiring between 2025 and 2030[69]. - The XCART and XDNASE patent families include recently filed applications with expiration dates extending to 2042[69]. - The company has received patent protection for therapeutics using PolyXen technology, including PSA-EPO and PSA-insulin[73]. - Patent protection has been granted for the production of PSA and the removal of endotoxin during purification, achieving a molecular weight polydispersity of 1.1 or lower[74]. - The XDNASE technology covers the use of DNase for cancer treatment and side effect amelioration, applicable alone or in combination with other therapies[75]. - Patents issued in the U.S. can provide exclusionary rights for twenty years from the earliest effective filing date, with potential extensions up to five years[76]. Company Structure and Workforce - The company employed four full-time employees as of December 31, 2023[128]. - The company utilizes specialists in various fields, including regulatory affairs and clinical development, to complement its professional staff[129]. Competitive Landscape - The biotechnology and pharmaceutical industries are characterized by intense competition, with competitors having greater financial resources and expertise[130]. - Key competitive factors for the company's product candidates include efficacy, safety, side effects, convenience, price, and reimbursement availability[132]. - The company faces competition from existing therapies and new therapies that may become available in the future, which could impact its market position[133]. - The company will compete with currently approved treatments for pancreatic cancer, including Gemcitabine and Abraxane, as well as recently approved therapies like NALIRIFOX[135]. - There have been late-stage clinical failures of compounds for advanced pancreatic ductal adenocarcinoma (PDAC), indicating a challenging development landscape[136]. - Current competing drug delivery platforms include PEGylation, Fc-fusion, and albumin-fusion, among others, indicating a competitive landscape in drug development[140].

For the transition period from to Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37937 XENETIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37937 XENETIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37937 XENETIC BIOSCIENCES, INC. (Registrant's telephone number, including area code) Securities registered pursuant to Sec ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORTS PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission File Number: 001-37937 XENETIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of i ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37937 XENETIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdic ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37937 XENETIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37937 XENETIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 45-2952962 (IRS Employer Identification No.) 40 Speen Street, Sui ...